Judicial scales of justice and legal jurisprudence volumes in federal courtroom
Federal appellate judicial chambers presiding over securities fraud proceedings.

BOSTON, Massachusetts — A senior vice president of regulatory affairs at a public biomedical firm has been sentenced to 54 months in federal prison following a guilty plea to securities fraud and illicit insider trading during critical FDA clinical trial reviews.

Incident Overview and Key Developments

Judicial filings established that the defendant liquidated over 220,000 corporate shares through private secondary trust vehicles immediately after receiving non-public notifications that a flagship cardiovascular implant had failed primary safety benchmarks.

  • Prosecuting Jurisdiction: District of Massachusetts Federal Court.
  • Financial Penalty Imposed: $3.4 million in criminal fines plus $8.9 million in disgorgement.
  • Prison Term: 54 months incarceration followed by 3 years supervised release.

Forensic Trading Telematics and Electronic Discovery

Investigators from the SEC Market Abuse Unit utilized automated pattern detection algorithms to cross-reference trading volumes with internal corporate server access timestamps. The analysis confirmed that sell orders were initiated within 42 minutes of the adverse clinical trial memorandum distribution.

Transaction Date Shares Liquidated Realized Price Loss Avoided
March 14, 2025 85,000 Shares $42.50 / Share $2.84 Million
March 18, 2025 135,000 Shares $41.80 / Share $4.42 Million
Post-Drop Price 0 Shares $9.15 / Share Total Avoided: $7.26M

Restitution for Harmed Retail Shareholders

The court ordered that all disgorged funds be allocated toward a Fair Fund administered under federal judicial supervision to compensate retail and institutional shareholders who purchased shares during the artificial price inflation window.

Leave a Reply

Your email address will not be published. Required fields are marked *